H.B. Fuller Company, together with its subsidiaries, formulates, manufactures, and markets adhesives, sealants, coatings, polymers, tapes, encapsulants, additives, and other specialty chemical products. It operates through three segments: Hygiene, Health and Consumable Adhesives; Engineering Adhesives; and Construction Adhesives. The Hygiene, Health and Consumable Adhesives segment produces and supplies specialty industrial adhesives, such as thermoplastic, thermoset, reactive, water-based, and solvent-based products for applications in various markets, including packaging, converting, nonwoven and hygiene, and health and beauty. The Engineering Adhesives segment produces and supplies high performance industrial adhesives comprising reactive, light cure, two-part liquids, polyurethane, silicone, film, and fast cure products to the durable assembly, performance wood and textile, transportation, electronics, clean energy, aerospace and defense, appliance, heavy machinery, and insulating glass markets. The Construction Adhesives segment provides products used for tile setting, commercial roofing, heating, ventilation, and air conditioning and insulation applications, as well as caulks and sealants for the consumer market and professional trade. The company sells its products directly to customers, as well as through distributors and retailers in North America, Latin America, Europe, India, the Middle East, Africa, and the Asia Pacific. H.B. Fuller Company was founded in 1887 and is headquartered in Saint Paul, Minnesota.

H. B. Fuller Company

Fulcrum Lithium Ltd. ( ($AU:FUL) ) has provided an announcement. Fulcrum Lithium has secured regulatory approval from the U.S. Bureau of Land Manag...

Fulcrum Lithium Advances Alkali Flats Drilling as Lithium Prices Rebound

H.B. Fuller Company (($FUL)) has held its Q4 earnings call. Read on for the main highlights of the call. H.B. Fuller Trades Near-Term Growth for St...

H.B. Fuller Leans on Margins in 2026 Earnings Pivot

Bank of America Securities analyst Tazeen Ahmad maintained a Sell rating on Fulcrum Therapeutics today and set a price target of $7.00. According t...

Fulcrum Therapeutics (FULC) Receives a Sell from Bank of America Securities

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Fulcrum Therapeutics (FULC – Research Report), Teladoc (TDOC – Re...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fulcrum Therapeutics (FULC), Teladoc (TDOC) and MDxHealth (MDXH)

An announcement from Fulcrum Therapeutics ( ($FULC) ) is now available. On January 12, 2026, Fulcrum Therapeutics updated its corporate presentatio...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	FUL	$60.07	-0.99%	381.86K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	FUL	$60.07	-1.0%	381.86K
3
4
5
6

FUL

FUL

Get H. B. Fuller Company Data in Excel

Get H. B. Fuller Company Data in Excel